Travere Therapeutics (TVTX) Inventory Average (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly Inventory Average came in at $6.1 million in Q1 2026, up 20.72% YoY from $5.1 million in Q1 2025, and up 7.07% on a QoQ basis from $5.7 million in Q4 2025.
Travere Therapeutics (TVTX) Inventory Average (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of Inventory Average data on file, last reported at $6.1 million in Q1 2026.
- Quarterly Inventory Average rose 20.72% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (up 20.72% YoY) and the FY2025 annual result came in at $6.0 million, down 22.65% from the prior year.
- Inventory Average advanced to $6.1 million in Q1 2026, from $5.7 million in the prior quarter.
- In the past five years, Inventory Average ranged from a high of $19.8 million in Q3 2023 to a low of $4.0 million in Q2 2025.
- A 5-year average of $7.7 million and a median of $6.2 million in 2024 frame the typical range for Inventory Average.
- Annual changes were most pronounced in 2023 — Inventory Average soared 164.84% — and 2024, when it slumped 68.81%.
- Tracing TVTX's Inventory Average over 5 years: stood at $5.9 million in 2022, then jumped by 155.36% to $15.1 million in 2023, then tumbled by 58.4% to $6.3 million in 2024, then slipped by 9.02% to $5.7 million in 2025, then grew by 7.07% to $6.1 million in 2026.
- The last three Inventory Average figures came in at $6.1 million (Q1 2026), $5.7 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 707.10 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 355,998.06 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 90.57 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 137.65 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 7.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.10 Mn |
| Mar 31, 2026 | 6.12 Mn |
| Dec 31, 2025 | 5.71 Mn |
| Sep 30, 2025 | 4.82 Mn |
| Jun 30, 2025 | 4.01 Mn |
| Mar 31, 2025 | 5.07 Mn |
| Dec 31, 2024 | 6.28 Mn |
| Sep 30, 2024 | 6.17 Mn |
| Jun 30, 2024 | 5.25 Mn |
| Mar 31, 2024 | 6.97 Mn |
| Dec 31, 2023 | 15.09 Mn |
| Sep 30, 2023 | 19.77 Mn |
| Jun 30, 2023 | 12.74 Mn |
| Mar 31, 2023 | 5.62 Mn |
| Dec 31, 2022 | 5.91 Mn |
| Sep 30, 2022 | 7.46 Mn |
| Jun 30, 2022 | 7.08 Mn |
| Mar 31, 2022 | 6.92 Mn |
| Dec 31, 2021 | 6.96 Mn |
| Sep 30, 2021 | 7.01 Mn |